Epiomic Epidemiology Series: Pulmonary Hypertension Forecast in 8 Major Markets 20152025 [Updated: 11082015] Prices from USD $6100

12:06 EDT 23 Jun 2017 | BioPortfolio Reports

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Pulmonary Hypertension in 8 Major Markets
Pulmonary Hypertension PH is a condition in which pulmonary arterial pressure is 25 mmHg or greater, measured via a cardiac catheterisation. There is a number of underlying causes for this syndrome and can be groups into different classifications according to the Dana Point. This report provides the current prevalent population for PH across 8 Major Markets USA, France, Germany, Italy, Spain, UK, Brazil and Japan split by gender and 5year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of PH. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a valueadded level of insight from the analysis team at Black Swan, several of the main symptoms and comorbidities of PH have been quantified and presented alongside the overall prevalence figures. These subpopulations within the main disease are also included at a country level across the 10year forecast snapshot.
Main symptoms and comorbidities for PH include:
Fibrotic Diseases
Cardiovascular Diseases
o Valvular Dysfunction
o Congenital Heart Disease
Thyroid Disease
Deep Vein Thrombosis DVT and Thrombotic Events
Obstructive Sleep Apnoea OSA
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
Able to quantify patient populations in global PH's market to target the development of future products, pricing strategies and launch plans.
Gain further insight into the prevalence of the subdivided types of PH and identify patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Provide a level of understanding on the impact from specific comorbid conditions on PH's prevalent population.
Identify subpopulations within PH which require treatment.
Gain an understanding of the specific markets that have the largest number of PH patients.

Original Article: Epiomic Epidemiology Series: Pulmonary Hypertension Forecast in 8 Major Markets 20152025 [Updated: 11082015] Prices from USD $6100


More From BioPortfolio on "Epiomic Epidemiology Series: Pulmonary Hypertension Forecast in 8 Major Markets 20152025 [Updated: 11082015] Prices from USD $6100"

Quick Search


Relevant Topics

Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of affected individuals. Symptoms can range from mild breathles...

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...